Using RNA Analytics, Bioinformatics, and Machine Learning/AI
AMPEL Genomic Platform (AGP®) and
genomic blood or biopsy tests for patients:
Evaluate disease status
Identify molecular pathways
Predict drug options
Precise Clinical Care Solutions
AMPEL Genomic Platform (AGP®), Bioinformatic Tools and Machine Learning Algorithms (AI/ML)
Step 1:
Create A Genomic Fingerprint
Comprehensive RNA analytics of gene expression from blood or biopsy to determine disease activity, molecular pathways and drug options.
Step 2:
Analyze The Fingerprint With ML/AI
Covers >95% of all known genes and is disease agnostic.
Step 3:
Provide Decision Making Support
Identification of patient’s immune status, provides decision support for most appropriate treatment options.
Step 4:
Market ready and Reproducible
First-in-class CLIA-certified gene-based Lab Developed Test (LDT).
Key Stats
Lead product LuGENE® expected Q2 2023. DermaGENE® expected Q1 2024.
Products for other indications available for partnering.
95%
coverage of all known genes and is disease agnostic
20,000+
autoimmune and normal patient gene expression profiles with rich clinical information – world’s largest for Lupus
35+
technology patents filed & pending with the freedom to operate
20+
pharma customers validate the technology
5+
additional autoimmunity products in development
Featured News
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Local company unveils blood test to find treatments for chronic pain
Local company unveils blood test to find treatments for chronic pain
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee
About the Founders
